Elaine Kingwell is a post-doctoral fellow in the multiple sclerosis (MS) research group at the University of British Columbia (UBC) and is funded by a Michael Smith Foundation for Health Research post-doctoral fellowship. Her current research interests include the epidemiology of MS; the natural course of MS and the influence of disease modifying therapies; cancer, co-morbidities, causes of death and survival with MS; epidemiological methods and use of linked administrative health datasets for population health research.
Kingwell is also involved in research projects on women’s reproductive health and osteoporosis through the Centre for Menstrual Cycle and Ovulatory Research (CeMCOR). She earned her PhD in epidemiology from UBC; MSc in neuroscience from the University of Calgary, and BSc in biology and psychology from the University of Wales (University College Swansea).
University: University of British Columbia
Department: Division of Neurology
Position: Post-Doctoral Fellow
Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain. 2012 Oct;135(Pt 10):2973-9. doi: 10.1093/brain/aws148.
Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):61-6. doi: 10.1136/jnnp-2011-300616.
Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology. 2010 Jun 1;74(22):1822-6. doi: 10.1212/WNL.0b013e3181e0f7e6.
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.
Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Mult Scler. 2011 Mar;17(3):361-7. doi: 10.1177/1352458510388823.